Filing Flows › Integra Lifesciences Holdings (IART) › Q1 2026
Integra Lifesciences Holdings (IART) Q1 2026 earnings results (first quarter 2026)
10-Q filed May 5, 2026
Integra Lifesciences Holdings (IART) reported revenue of $392M for the first quarter 2026 (Q1 2026), +2% from a year earlier and -10% from the quarter before. Operating margin was 2.9%, net loss $4.6M (1.2% of revenue).
Integra Lifesciences Holdings, Q1 2026: revenue $392M (+2% year over year), operating margin 2.9%, net loss $4.6M, operating cash flow $9.8M. The chart follows the revenue to costs, profit and cash.
| Q1 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $392M | -10% | +2% |
| Operating profit | $11.5M | -50% | — |
| Net earnings | −$4.6M | — | — |
| Operating cash flow | $9.8M | -17% | — |
What changed
Revenue was $391.9M in Q1 2026, up 2% year over year and down 10% from the previous quarter. Specialty Surgery was the largest line at 72% of revenue. Tissue Reconstruction added $6.8M year over year (up 7%), 73% of the total change.
Operating profit was $11.5M, a 2.9% margin (up 7.0 points year over year). Total costs fell 4% while revenue rose 2%. The quarter ended with a net loss of $4.6M, wider than the previous quarter's $1.7M loss. Net interest and other expense of $13.9M was the main reason.
Operating cash flow was $9.8M. Non-cash charges added back $5.2M of share-based compensation. Working capital and other items added $9.3M. Capital expenditures of $14.8M exceeded it, leaving free cash flow of −$5.0M.
Questions
What was Integra Lifesciences Holdings' revenue in the first quarter 2026?
Integra Lifesciences Holdings (IART) reported revenue of $392M for the first quarter 2026 (Q1 2026), +2% from a year earlier and -10% from the quarter before.
Was Integra Lifesciences Holdings profitable in the first quarter 2026?
Operating profit was $11.5M (2.9% of revenue) and net loss $4.6M.